MediWound (NASDAQ:MDWD) Stock Passes Above 50-Day Moving Average – What’s Next?

MediWound Ltd. (NASDAQ:MDWD) shares passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $18.28 and traded as high as $19.00. MediWound shares last traded at $18.76, with a volume of 54,174 shares changing hands.

Analyst Ratings Changes

Several analysts have recently weighed in on MDWD shares. Zacks Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $36.00 target price (up previously from $31.00) on shares of MediWound in a research report on Friday, November 21st. Finally, Wall Street Zen raised MediWound from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, MediWound presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.50.

MediWound Trading Down 1.5%

The stock’s 50 day moving average price is $18.28 and its two-hundred day moving average price is $18.63. The firm has a market capitalization of $208.05 million, a PE ratio of -9.87 and a beta of 0.07.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.57. MediWound had a negative return on equity of 62.11% and a negative net margin of 98.43%.The firm had revenue of $5.43 million for the quarter, compared to analysts’ expectations of $6.56 million. Analysts expect that MediWound Ltd. will post -2.66 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its stake in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 481 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares during the period. Corebridge Financial Inc. increased its stake in shares of MediWound by 17.1% during the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 665 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 999 shares during the period. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.